Skip to main content
LD

Loop Dx

Loop Diagnostics develops a patented in vitro cellular immunoassay that detects sepsis by identifying immune activity biomarkers within the first hour of bloodstream infection, offering three times the sensitivity of leading competitors. This rapid diagnosis addresses the critical challenge of timely sepsis detection, significantly improving treatment outcomes and reducing mortality rates associated with this life-threatening condition.

Barcelona, SpainFounded 201892K+ followers
Updated 4 months ago

Funding

$780K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Funding rounds are not available yet.

Founders

Product

Problem

Sepsis, a life-threatening condition, has a high mortality rate and significant healthcare costs due to the challenges in timely diagnosis. Current diagnostic methods rely on clinical signs and symptoms, often indicating advanced disease, and pathogen identification can be slow. This results in delayed treatment, increased disease severity, and unnecessary antibiotic use.

Solution

Loop Diagnostics has developed an in vitro cellular immunoassay for rapid sepsis detection. Their patented method identifies immune activity biomarkers within one hour of bloodstream infection, offering three times the sensitivity of leading competitors. This early detection enables healthcare providers to initiate accurate treatment sooner, reducing disease severity and minimizing the need for broad-spectrum antibiotics. The diagnostic process is also significantly faster than traditional pathogen identification methods.

Target Audience

The primary target audience includes healthcare providers, hospitals, and clinical laboratories seeking rapid and accurate sepsis diagnostics for early intervention and improved patient outcomes.

Features

  • Patented in vitro cellular immunoassay technology
  • Detects sepsis within one hour of bloodstream infection
  • Three times the sensitivity compared to leading competitors
  • Identifies immune activity biomarkers for early detection
  • Faster than pathogen identification
  • Enables earlier and more accurate treatment decisions
This profile is AI-generated and may contain inaccuracies.